RAFAEL HOLDINGS, INC. Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
RAFAEL HOLDINGS, INC. (RFL) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$697.00 thousand for the 3-month period ending 2023-04-30, per its 10-Q filed 2023-06-13.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2023-06-13
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-04-30 was -$697.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2023-01-31 was $268.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2022-10-31 was $103.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2022-07-31 was -$15.00K.
- RAFAEL HOLDINGS, INC. marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$63.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2023-04-30 | -$697.00K 10-Q · filed 2023-06-13 | -$429.00K derived: sum of 2 quarters · filed 2023-06-13 | -$326.00K 10-Q · filed 2023-06-13 | -$341.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $268.00K 10-Q · filed 2023-03-14 | $371.00K 10-Q · filed 2023-03-14 | $356.00K derived: sum of 3 quarters · filed 2023-03-14 | $308.00K derived: sum of 4 quarters · filed 2023-06-13 |
| 2022-10-31 | $103.00K 10-Q · filed 2022-12-13 | $88.00K derived: sum of 2 quarters · filed 2022-12-13 | $40.00K derived: sum of 3 quarters · filed 2023-06-13 | |
| 2022-07-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | -$63.00K derived: sum of 2 quarters · filed 2023-06-13 | -$63.00K 10-K · filed 2022-10-31 | |
| 2022-04-30 | -$48.00K 10-Q · filed 2023-06-13 | -$48.00K 10-Q · filed 2023-06-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |